Publications by authors named "Tomonari Kunihisa"

Article Synopsis
  • * Researchers analyzed serum samples from eight patients before and after surgery to quantify the levels of these exosomes using specialized beads.
  • * Findings indicated that levels of CD63 and CD9, as well as CD9 and HER2, decreased post-surgery in patients with HER2-positive tumors, suggesting these exosomes could be potential biomarkers for tracking tumor burden.
View Article and Find Full Text PDF
Article Synopsis
  • - A multidisciplinary approach using Bone Metastasis Cancer Boards (BMCBs) has been utilized since 2013 to manage patients at risk of skeletal-related events (SREs), focusing on teamwork for the best treatment outcomes.
  • - A pregnant 41-year-old woman with breast cancer and multiple bone metastases received coordinated care through a BMCB, which led to a successful cesarean section and subsequent rehabilitation therapy.
  • - The BMCB not only addressed the patient’s immediate treatment needs but also helped improve her daily activities and overall well-being, highlighting the potential of BMCBs in preventing SREs and enhancing rehabilitation for similar patients.
View Article and Find Full Text PDF

Background/aim: BRCA1/2 mutations in breast cancer cells impair homologous recombination and promote alternative end joining (Alt-EJ) for DNA-damage repair. DNA polymerase theta, encoded by POLQ, plays a crucial role in Alt-EJ, making it a potential therapeutic target, particularly in BRCA1/2-mutant cancers. Methionine restriction is a promising approach to target cancer cells due to their addiction to this amino acid.

View Article and Find Full Text PDF

BRCA1/2 genetic testing has become clinically important in breast cancer care, but increasing demand may put a burden on the shortage of healthcare professionals. We performed a single-center, pilot randomized controlled study to assess the effectiveness of employing a video educational tool that included standard pre-test genetic counseling elements related to BRCA1/2. Patients with operable breast cancer who met the criteria for genetic testing based on age, sex, subtype, and family history were recruited.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the distribution of BRCA1/2 germline pathogenic variants, particularly focusing on a founder mutation (BRCA2 c.5576_5579del) among breast cancer patients in Japan.
  • Conducted at Kobe University Hospital and three other institutions, the study analyzed genetic testing results from 38 breast cancer patients between 2018 and 2021, comparing clinical characteristics and breast cancer subtypes among different genetic carriers.
  • Results revealed that BRCA2 c.5576_5579del was prevalent, especially in Kakogawa City, with a significant correlation between this mutation and triple negative breast cancer, highlighting the need for further research on its distribution.
View Article and Find Full Text PDF

Background/aim: Breast cancer that is estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor-2 (HER2)-negative is termed triple-negative breast cancer (TNBC). Cytotoxic chemotherapy remains the first choice of treatment against TNBC due to lack of specific therapeutic targets. TNBC is not classified based on therapeutic targets, but recently, the development of targeted therapies - including immune checkpoint inhibitors and poly (adenosine diphosphate-ribose) polymerase inhibitors - has gained attention.

View Article and Find Full Text PDF

Background/aim: Methionine addiction is the elevated requirement for exogenous methionine for growth and survival of cancer cells, termed the Hoffman effect. Methionine-addicted cancer cells synthesize normal or excess amounts of methionine but still need an external source of methionine. Methionine restriction (MR) by either a methionine-free medium or in vivo by a low-methionine diet or by methioninase, selectively arrests cancer cells in the late S/G cell cycle phase, but not normal cells.

View Article and Find Full Text PDF

A 56-year-old female patient with left breast cancer presented at our hospital. Preoperative CT scan showed an isolated bilateral pectoralis major muscle defect and abnormal muscle originating from the entire sternum and inserting in the lower ribs and rectus sheath. Total mastectomy and axillary lymph node dissection were performed.

View Article and Find Full Text PDF

Background/aim: Aldehyde dehydrogenase (ALDH) 1A1 is a well-known marker for cancer stem cells (CSCs), characterized by self-renewal capacity and multidrug resistance in breast cancer. We developed a near-infrared turn-on fluorescence probe for ALDH1A1, C5S-A, which is suitable for observing and analyzing viable cells. Here, we demonstrated the utility of C5S-A in CSC research using breast cancer cell lines.

View Article and Find Full Text PDF

The high incidence and mortality of cancer make it a global health issue. However, conventional cancer therapies have several disadvantages, especially serious side effects due to low selective toxicity to cancer cells. Gold nanoparticles (AuNPs) are an excellent drug carrier, enhance drug delivery efficiency, and hold promise for photothermal and radiation therapies.

View Article and Find Full Text PDF

A 44-years-old woman who underwent bilateral mastectomy was treated with chemotherapy after axillary lymph nodes and liver metastases recurrence. She was referred to our hospital for BRCA1/2 germline test and the test revealed BRCA2 pathogenic mutation. Before the administration of olaparib as the fourth-line therapy, liver dysfunction, caused by extensive liver metastasis, was observed.

View Article and Find Full Text PDF

Background/aim: Exosomes are produced by normal and cancer cells. Exosomes are found in the serum of cancer patients and have been used for diagnosis and prognosis. Recently tears from non-cancer patients have been found to contain exosomes.

View Article and Find Full Text PDF